Please find attached Newspaper Advertisement - Audited financial results of the Company for the quarter and financial year ended on March 31, 2026.
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma has published its audited financial results for Q4 FY26 and the full financial year ended March 31, 2026. Consolidated revenue grew 17% year-on-year to Rs 14,278 Crores, while standalone revenue increased 10% to Rs 10,421 Crores. Standalone profit after tax rose 18% to Rs 2,038 Crores compared to Rs 1,725 Crores in the previous year. The company reported Q4 standalone profit of Rs 714 Crores on revenue of Rs 2,582 Crores. Basic EPS for FY26 stands at Rs 46.35. The debt equity ratio improved significantly from 0.52 to 0.34, indicating better financial leverage management.
Strong revenue and profit growth demonstrates solid operational performance. The improved debt position is positive for shareholders. However, the decline in consolidated PAT compared to FY25 (Rs 1,938 Cr vs Rs 2,007 Cr) may raise questions about subsidiary performance.